OABI Stock Analysis: Buy, Sell, or Hold?
OABI - OmniAb, Inc. Common Stock
$2.50
-0.12 (-4.58%)
▼
5d:
-3.47%
30d:
+77.3%
90d:
+38.12%
BUY
HIGH Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: May 07, 2026
0d
Get Alerted When OABI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: OABI shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: OABI shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: OABI is currently trading at $2.50, which is considered slightly high relative to its 30-day fair value range of $1.51 to $2.56.
Technical Outlook: Technically, OABI is in a uptrend. Immediate support is located at $2.40, while resistance sits at $2.79. Short-term momentum is weak, with the stock down 4.6% recently.
Market Sentiment: OABI has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $7.33 (+193.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, OABI is in a uptrend. Immediate support is located at $2.40, while resistance sits at $2.79. Short-term momentum is weak, with the stock down 4.6% recently.
Market Sentiment: OABI has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $7.33 (+193.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$1.51 -
$2.56
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
79.2%
All Signals
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.6%)
- BULLISH: Trading 193.3% below Wall St target ($7.33)
Trading Range Analysis
30-Day Trading Range
$1.51 -
$2.56
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$0.17
(7.0%)
Support & Resistance Levels
Support Level
$2.40
Resistance Level
$2.79
Current Trend
Uptrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.75
Wall Street Target
$7.33
(+193.3%)
Revenue Growth (YoY)
247.3%
Profit Margin
-187.6%
Share & Embed Analysis
Last updated: June 03, 2026 7:58 PM ET
Data refreshes hourly during market hours. Next update: 8:58 PM
Data refreshes hourly during market hours. Next update: 8:58 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OABI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
12
Sells
Net
INSIDERS SELLING
Recent Transactions
Charles S Berkman
SELL
7157 shares
2026-04-07
Kurt A Gustafson
SELL
6913 shares
2026-04-07
Matthew W Foehr
SELL
19244 shares
2026-04-07
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$55 | 66 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 53 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 55 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$118 | 53 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 59 HOLD |
